

## TABLE OF CONTENTS

<b>Contents</b>	<b>Page No.</b>
<b>Abstract</b>	<b>i-iv</b>
<b>Declaration</b>	<b>v</b>
<b>Certificate</b>	<b>vi</b>
<b>Acknowledgements</b>	<b>vii-viii</b>
<b>Table of Contents</b>	<b>viii-xi</b>
<b>List of Tables</b>	<b>xii</b>
<b>List of Figures</b>	<b>xiii-xv</b>
<b>Abbreviations</b>	<b>xvi-xix</b>

### **CHAPTER-I**

<b>Introduction</b>	<b>1-5</b>
Bibliography	6-11

## TABLE OF CONTENTS

<b>Contents</b>	<b>Page No.</b>
<b>Chapter II</b>	
<b>Review of Literature</b>	<b>12-51</b>
2.1 Obesity and type 2 diabetes (T2D): Epidemiological prevalence	12
2.2 Obesity mediated type 2 diabetes: Interrelation	13
2.3 Obesity mediated type 2 diabetes: Interrelation	13-14
2.4 Adipose tissue inflammation leading to insulin resistance: Mechanism	15-16
2.5 Inflammation and T2D: A brief introduction	17-18
2.6 Adenosine signalling pathway: Role and target of treatment	19-21
2.7 Toll-like receptor signalling pathway: Introduction and role in resolving obesity underlying inflammation	21-23
2.7.1 TLRs: Structure and classification	21
2.7.2 TLR4-LPS mediated signaling pathway: Introduction and Mechanism	22
2.7.3 MyD88-dependent pathway	23
2.7.4 MyD88-independent/TRIF-dependent pathway	24
2.8 TLR4 signaling pathway, chronic inflammation and T2D	25
2.9 Protein kinase C (PKC) mediated impairment of insulin signaling pathway	26
2.10 Small molecules and their roles in combating health complications to metabolic disorders	27
2.11 Natural products and their derivatives: their role as drug molecules	27-28

2.12 Indirubin and Indirubin derivatives	29-32
2.12.1 Indirubin and its derivatives as anti cancer and anti-inflammatory agent	29-31 31-32
2.12.2 Indirubin-3'-monoxime (I3M)	
2.13 Vanillin (VNL): A brief introduction and its anti-cancer, anti-microbial and anti-inflammatory attribute	33-36
Bibliography	36-51

---

### **CHAPTER III**

<b>Materials and Methods</b>	<b>52-66</b>
3.1 Reagents	52-53
3.2 Cell culture and treatments	53-54
3.3 Development of A <sub>2A</sub> AR stable clone	54
3.4 Radioligand-binding assay	54
3.5 Glucose uptake assay	55
3.6 Cell viability assay	55
3.7 Immunoblotting	56
3.8 Coimmunoprecipitation	56
3.9 Immunofluorescence analysis	57
3.10 Semi-quantitative RT-PCR and real-time quantitative PCR	57
3.11 Enzyme-linked immunosorbent assay (ELISA)	59
3.12 Chromatin immunoprecipitation (ChIP) assay	60
3.13 Cyclic AMP assay	60
3.14 Glycerol release assay	60
3.15 Luciferase reporter assay	61
3.16 RNA interference study	61
3.17 Surface plasmon resonance (SPR) analysis	62
3.18 In-vitro IRAK4 kinase assay	62
3.19 Flow cytometric analysis	63
3.20 Site-directed mutagenesis	63
3.21 Animals and treatments	63
3.22 Molecular docking studies	64
3.23 Development of vanillin analogs	64
3.24 Statistical analysis	64-65
Bibliography	65

---

<b>CHAPTER IV</b>	
<b>Study the efficacy of different small molecules on the induction of insulin sensitivity through A<sub>2A</sub>AR signalling pathway</b>	<b>67-82</b>
4.1 Introduction	67
4.2 Results	
4.2.1 In-silico studies for screening of potential adenosine 2A receptor (A <sub>2A</sub> AR) agonists	68-69
4.2.2 Vanillin (VNL) and indirubin-3'-monoxime (I3M) prevents lipid induced insulin resistance through the activation of A <sub>2A</sub> AR	70-72
4.2.3 Vanillin stimulates A <sub>2A</sub> AR signalling and promotes anti-inflammatory state of adipocytes	72-75
4.2.4 Activation of A <sub>2A</sub> AR by vanillin attenuates lipid induced adipocyte inflammation	76-77
4.3 Discussions	77-78
Bibliography	79-82
<hr/>	
<b>Chapter V</b>	
<b>To investigate the role of indirubin 3'-monoxime (I3M)-induced A<sub>2A</sub>AR signalling in alleviating lipid-induced adipocyte insulin resistance</b>	<b>83-98</b>
5.1 Introduction	83-84
5.2 Results	
5.2.1 I3M directly binds with and stimulates A <sub>2A</sub> AR signaling	85-87
5.2.2 I3M promotes anti-inflammatory state in adipocytes through the activation of A <sub>2A</sub> AR signalling	88-90
5.2.3 Activation of A <sub>2A</sub> AR by I3M attenuates lipid induced adipocyte inflammation	90-92
5.3 Discussions	92-94
Bibliography	95-98
<hr/>	
<b>CHAPTER VI</b>	
<b>Vanillin acts as a potent IRAK4 inhibitor that impairs LPS-induced TLR4 signalling and inflammation</b>	<b>99-125</b>
6.1 Introduction	99-100
6.2 Results	100-106
6.2.1 Vanillin (VNL) attenuates LPS-induced TLR4 activation	106-108
6.2.2 Vanillin prevents inflammation in macrophages expressing the constitutively active forms of IRAK4/1	
6.2.3: VNL directly binds and inhibits IRAK4 kinase activity	108-114
6.2.4. Vanillin abrogates LPS-induced TLR4 activation and inflammation <i>in-vivo</i>	114-115
6.3 Discussion	115-119
Bibliography	120-125
<hr/>	

---

<b>Chapter VII</b>	<b>126-130</b>
<b>Conclusion and future perspectives</b>	
7.1 Conclusion	126-130
7.2 Future Prospects	130

---

<b>List of Publications</b>	<b>131</b>
-----------------------------	------------

---